This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. AVTE, NLTX, BIOA, ELYM, CYBN, VIRI, WHWK, OSTX, ATNM, and NBRVShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Eliem Therapeutics (ELYM), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Actinium Pharmaceuticals (ATNM), and Nabriva Therapeutics (NBRV). Ritter Pharmaceuticals vs. Its Competitors Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Eliem Therapeutics Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Actinium Pharmaceuticals Nabriva Therapeutics Aerovate Therapeutics (NASDAQ:AVTE) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, media sentiment, analyst recommendations and risk. Which has more volatility and risk, AVTE or RTTR? Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, meaning that its stock price is 143% less volatile than the S&P 500. Is AVTE or RTTR more profitable? Ritter Pharmaceuticals' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Ritter Pharmaceuticals N/A N/A -162.05% Does the media prefer AVTE or RTTR? In the previous week, Aerovate Therapeutics had 2 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 2 mentions for Aerovate Therapeutics and 0 mentions for Ritter Pharmaceuticals. Aerovate Therapeutics' average media sentiment score of 1.68 beat Ritter Pharmaceuticals' score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Aerovate Therapeutics Very Positive Ritter Pharmaceuticals Neutral Which has higher earnings & valuation, AVTE or RTTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.56Ritter PharmaceuticalsN/AN/A-$10.13MN/AN/A Do insiders and institutionals have more ownership in AVTE or RTTR? 0.8% of Ritter Pharmaceuticals shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryAerovate Therapeutics beats Ritter Pharmaceuticals on 6 of the 9 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$96.69M$934.71M$5.87B$10.13BDividend YieldN/A4.84%5.68%4.60%P/E Ratio-3.271.1074.5225.93Price / SalesN/A26.64517.44183.79Price / CashN/A19.5637.5660.44Price / Book20.956.6912.166.29Net Income-$10.13M-$4.50M$3.28B$270.77M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$2.10+0.2%N/A+1,248.4%$96.69MN/A-3.277AVTEAerovate TherapeuticsN/A$7.48-3.7%N/A-88.2%$216.81MN/A-2.5020Positive NewsHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$19.45-2.5%N/A-50.2%$182.79MN/A-6.2590High Trading VolumeBIOABioAge Labs0.2029 of 5 stars$4.98-2.2%N/AN/A$182.48MN/A0.00N/APositive NewsELYMEliem TherapeuticsN/A$2.47+3.3%N/A-70.0%$152.03MN/A-4.669News CoverageCYBNCybin2.6858 of 5 stars$6.43+2.6%$85.00+1,221.9%N/A$151.68MN/A-1.4750Positive NewsGap DownHigh Trading VolumeVIRIVirios TherapeuticsN/A$4.90flat$5.00+2.0%+2,484.1%$94.36MN/A-18.155WHWKWhitehawk Therapeutics1.1984 of 5 stars$1.80+0.6%N/AN/A$84.36M$25.98M-30.0021Positive NewsGap DownOSTXOS Therapies1.7699 of 5 stars$2.19-2.2%$18.00+721.9%-35.7%$69.30MN/A-2.77N/AAnalyst ForecastATNMActinium Pharmaceuticals3.071 of 5 stars$1.60flat$4.50+181.3%-16.2%$49.91MN/A-1.1530Positive NewsShort Interest ↑NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors BioAge Labs Competitors Eliem Therapeutics Competitors Cybin Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors OS Therapies Competitors Actinium Pharmaceuticals Competitors Nabriva Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
